CRISPR Therapeutics AG
NASDAQ:CRSP

Watchlist Manager
CRISPR Therapeutics AG Logo
CRISPR Therapeutics AG
NASDAQ:CRSP
Watchlist
Price: 37.82 USD 0.13% Market Closed
Market Cap: 3.2B USD

Intrinsic Value

CRSP's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

The intrinsic value of one CRSP stock under the Base Case scenario is 60.24 USD. Compared to the current market price of 37.82 USD, CRISPR Therapeutics AG is Undervalued by 37%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

CRSP Intrinsic Value
60.24 USD
Undervaluation 37%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation History
CRISPR Therapeutics AG

CRSP
Valuation History
HIDDEN
Show
Valuation History Unavailable

Historical valuation for CRSP cannot be conducted due to limitations such as insufficient data or other constraints.

Valuation In Progress...
Valuation In Progress...
0%

Fundamental Analysis

Company Overview
Loading...
Business Segments
Loading...
Management
Loading...
Contacts
Loading...
How do you feel about CRSP?
Bearish
Neutral
Bullish
AI Assistant
AI Assistant
Ask me anything about CRISPR Therapeutics AG
Financials
Annual
Quarterly
TTM

Balance Sheet Decomposition
CRISPR Therapeutics AG

Current Assets 1.9B
Cash & Short-Term Investments 1.9B
Receivables 25m
Other Current Assets 8.3m
Non-Current Assets 304.9m
PP&E 277.6m
Other Non-Current Assets 27.3m
Efficiency

Free Cash Flow Analysis
CRISPR Therapeutics AG

Last Value
3-Years Average
FCF Margin
Conversion Rate

Earnings Waterfall
CRISPR Therapeutics AG

Revenue
37.3m USD
Operating Expenses
-503.9m USD
Operating Income
-466.6m USD
Other Expenses
100.3m USD
Net Income
-366.3m USD
Fundamental Scores

CRSP Profitability Score
Profitability Due Diligence

CRISPR Therapeutics AG's profitability score is 14/100. The higher the profitability score, the more profitable the company is.

Exceptional Revenue Growth Forecast
Negative 1-Year Revenue Growth
Declining ROE
Declining ROIC
14/100
Profitability
Score

CRISPR Therapeutics AG's profitability score is 14/100. The higher the profitability score, the more profitable the company is.

CRSP Solvency Score
Solvency Due Diligence

CRISPR Therapeutics AG's solvency score is 80/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Short-Term Solvency
Long-Term Solvency
Low D/E
80/100
Solvency
Score

CRISPR Therapeutics AG's solvency score is 80/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

CRSP Price Targets Summary
CRISPR Therapeutics AG

Wall Street analysts forecast CRSP stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for CRSP is 82.24 USD with a low forecast of 32.32 USD and a high forecast of 281.4 USD.

Lowest
Price Target
32.32 USD
15% Downside
Average
Price Target
82.24 USD
117% Upside
Highest
Price Target
281.4 USD
644% Upside
View Analyst Estimates
View Analyst Estimates

Dividends

CRISPR Therapeutics AG
does not pay dividends
Shareholder Yield

Current shareholder yield for CRSP is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Ownership

CRSP Insider Trading
Buy and sell transactions by insiders

CRSP News

Other Videos
What is the Intrinsic Value of one CRSP stock?

The intrinsic value of one CRSP stock under the Base Case scenario is 60.24 USD.

Is CRSP stock undervalued or overvalued?

Compared to the current market price of 37.82 USD, CRISPR Therapeutics AG is Undervalued by 37%.

Back to Top